

^{18}F -Fluorination of Unactivated C–H Bonds in Branched Aliphatic Amino Acids: Direct Synthesis of Oncological Positron Emission Tomography Imaging Agents

Matthew B. Nodwell,[†] Hua Yang,[‡] Milena Čolović,[§] Zheliang Yuan,^{†,‡} Helen Merkens,[§] Rainer E. Martin,^{*,†,⊕} François Bénard,^{*,§} Paul Schaffer,^{*,†,‡} and Robert Britton^{*,†,⊕}

[†]Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S2, Canada

[‡]Life Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada

[§]Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3 Canada

[⊕]Medicinal Chemistry, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland

S Supporting Information

ABSTRACT: A mild and selective photocatalytic C–H ^{18}F -fluorination reaction has been developed that provides direct access to ^{18}F -fluorinated amino acids. The biodistribution and uptake of three ^{18}F -labeled leucine analogues via LAT1 mediated transport in several cancer cell lines is reported. Positron emission tomography imaging of mice bearing PC3 (prostate) or U87 (glioma) xenografts using 5- ^{18}F -fluorohomoleucine showed high tumor uptake and excellent tumor visualization, highlighting the utility of this strategy for rapid tracer discovery for oncology.

Positron emission tomography (PET) uses radioisotopes to interrogate specific physiological processes in real time and in living systems.¹ Thus, PET is ideally suited for the early detection of tumors and metastases, and is an established modality for diagnosis, staging, and treatment planning of various malignancies.^{2,3} The selective imaging of cancers with PET often exploits radiotracers that target aberrant cellular metabolism or increased protein expression.⁴ For example, the widely used cancer diagnostic 2-deoxy-2- ^{18}F fluoro-D-glucose^{4,5} (^{18}F FDG (1), Figure 1) takes advantage of the




Figure 1. Radiotracers for PET imaging in oncology and ^{18}F -labeled analogues of leucine.

increased glucose uptake and glycolysis in many tumors. Increased amino acid (AA) uptake through overexpression of AA transporters is also a signature feature in cancers, and radiolabeled AAs (e.g., 2⁶ and 3⁷) are highly sought as imaging agents.^{2,3,8} The uptake of AAs by L-type AA transporters (LATs)⁹ is a particularly appealing target for PET radiotracers. Most notably, the LAT1 isoform transports branched and aromatic AAs, and is highly upregulated in several cancers (e.g., prostate, breast and brain) and at metastatic sites.^{9a}

Among the wide range of AAs transported by LAT1, leucine plays a uniquely important role in cancer biology as large cellular concentrations of leucine are required to trigger mTORC1 activation and support accelerated protein synthesis.¹⁰ Not surprisingly then, L-1- ^{11}C leucine represents a promising PET imaging agent.¹¹ Unfortunately, its widespread use is limited by a reliance on the rapidly decaying radionuclide ^{11}C ($t_{1/2} = 20.4$ min), which restricts use to PET clinics with on-site cyclotron facilities. The longer lived radionuclide ^{18}F ($t_{1/2} = 109.8$ min) is incorporated in the leucine mimic ^{18}F FACBC (4),¹² which was recently approved by the U.S. FDA for recurrent prostate cancer imaging.^{12a} Recently, the boramino acid ^{18}F Leu-BF₃ (5) was also reported,¹³ adding to the repertoire of radiolabeled leucine mimics. Notwithstanding these and other advances,⁸ there is no general synthetic strategy to effect selective ^{18}F -labeling of AAs such as leucine without significantly altering the parent structure or relying on prosthetic groups. Here, we describe the direct radiofluorination¹⁴ of unprotected, branched aliphatic amino acids. The PET imaging of mice bearing subcutaneous PC3 or U87 xenografts using a new ^{18}F -labeled analogue of leucine highlights the potential for this convenient reaction to rapidly access amino-acid-derived imaging agents for cancer.

We recently reported the decatungstate-catalyzed fluorination of unactivated C–H bonds,^{15a} and have applied this strategy to the selective fluorination of aliphatic^{15a,b} and benzylic^{15c} C–H bonds. This reaction involves hydrogen atom abstraction by a photoactivated decatungstate catalyst,¹⁶

Received: November 7, 2016

Published: March 1, 2017

followed by fluorine atom transfer¹⁷ from *N*-fluorobenzene-sulfonimide (NFSI) to the resultant carbon radical (e.g., **8**, Figure 2). Considering the high degree of selectivity observed




Figure 2. Decatungstate-catalyzed C–H fluorination applied to the production of 4-[¹⁸F]fluoroleucine (4-[¹⁸F]FL (**7**)).

for C–H fluorination at the branched position in esters of leucine^{15b} and valine,^{15a} we contemplated development of the photocatalytic C–H ¹⁸F-fluorination reaction depicted in Figure 2 using [¹⁸F]NFSI,¹⁸ a reagent that has been developed by Gouverneur and Luthra.^{18,19} This unique process would provide direct access to 4-[¹⁸F]FL (**7**)²⁰ or other radiolabeled AA substrates for LAT1 from readily available or natural AAs (e.g., **6**).

We began by exploring the fluorination of *L*-leucine-HCl using conditions previously reported by us for the large scale (~50 g) non-radioactive synthesis of 4-fluoroleucine methyl ester.^{15b} We were pleased to discover that this mild process is also compatible with direct fluorination of the unprotected amino acid, and that 4-FL could be produced in modest yield (~20%) after 1 h. Several reactor configurations (batch and flow) were evaluated and ultimately, a narrow-bore PTFE tube wrapped around a BLB lamp²¹ proved optimal, with ~60% conversion to 4-FL observed after only 40 min. Although separable by HPLC,²¹ the removal of leucine from 4-FL was ultimately deemed unnecessary as plasma concentrations of leucine range from 100 to 150 μM,²² making it unlikely that residual leucine would interfere with the pharmacokinetic

performance of the tracer. It was eventually found that a strong cation exchange resin retained the 4FL/leucine mixture and not NFSI, NHSI or other reaction byproducts, and that the purified AA mixture could then be rapidly eluted using aqueous base (without requirement for HPLC).

The synthesis of [¹⁸F]NFSI was accomplished using a modified version of the reaction reported by Luthra and Gouverneur.¹⁸ For our purposes,²³ a 5–10 min cyclotron irradiation of [¹⁸O]O₂ produced [¹⁸F]F₂ gas²⁴ from which ~1.5 GBq was trapped in the NaN(SO₂Ph)₂ → [¹⁸F]NFSI reaction mixture. Rapid (<5 min) purification of [¹⁸F]NFSI using a C18 SepPak afforded a solution of [¹⁸F]NFSI (0.2–0.5 GBq) in H₂O–CH₃CN with an impurity profile similar to that reported previously.^{18,21} Critically, this modified process avoids the drying of [¹⁸F]NFSI by azeotropic distillation (110 °C, 20 min) required for other uses of this reagent.¹⁸ The optimized photocatalytic C–H ¹⁸F-fluorination of *L*-leucine then simply involved adding the H₂O–CH₃CN solution of [¹⁸F]NFSI to a slurry of NaDT and *L*-leucine-HCl in H₂O. This mixture was irradiated for 40 min and purified as described for 4-FL above (Table 1). The specific activity for the 4-[¹⁸F]FL thus produced was ~7 MBq μmol⁻¹,²³ and the radiochemical purity of this material was >97%. The radiochemical yield for isolated and purified 4-[¹⁸F]FL (from [¹⁸F]NFSI) is 23 ± 3.3% (*n* = 4, decay corrected) with a radiosynthesis time of 50 min. Repetition of this reaction using *D,L*-leucine provided (±)-4-[¹⁸F]FL and allowed us to confirm by chiral HPLC that no racemization occurred during radiofluorination.²¹ It is notable that although this method uses low specific activity (SA) [¹⁸F]F₂ gas (~1 GBq μmol⁻¹),¹⁸ which may not be suitable for many purposes, clinically relevant doses of several amino acid radiotracers have been manufactured from [¹⁸F]F₂.^{19c,25}

We next examined the uptake of 4-[¹⁸F]FL in cancer cell lines LNCaP, PC3 and MCF7 showing various expression levels of LAT1. Notably, there was significant uptake in MCF7 cells, lower uptake in PC3 cells and almost no uptake in LNCaP cells,²¹ which mirrors the expected LAT1 mRNA expression levels (RMA log 2) in these cell lines of 13.05 (MCF7), 10.40 (PC3) and 6.49 (LNCaP).²⁶ The uptake of 4-[¹⁸F]FL in both PC3 and MCF7 cells was also significantly blocked by the addition of 2-amino-2-norbornancarboxylic acid (BCH), a LAT1 inhibitor,²⁷ suggesting that LAT1 is largely responsible for their 4-[¹⁸F]FL uptake. However, analysis of the biodistribution of 4-[¹⁸F]FL in healthy mice

Table 1. ¹⁸F-Fluorination of Unprotected Branched Aliphatic Amino Acids^a

¹⁸ F-labelled amino acid					
	7: 4-[¹⁸F]FL	8: 5-[¹⁸F]FHL	9: 5-[¹⁸F]FBAHL	10: 3-[¹⁸F]FV	11: 3-[¹⁸F]FI
radiochemical yield (%) ^{b,c}	23.3 ± 3.3%	27.9 ± 3.3%	29.8 ± 0.7%	6.4 ± 0.4%	<5% ^d
specific activity (MBq μmol ⁻¹) ^e	7.1 ± 1.9	6.3 ± 0.9	2.6 ± 0.6	3.4 ± 1.6	ND
bone uptake (%ID/g) ^b	11.9 ± 1.6	1.6 ± 0.1	1.2 ± 0.4	ND	ND

^aSee Supporting Information (SI) for reaction conditions. All radiosynthesis times including purification were less than 60 min and the radiochemical purity of each tracer was >97%. ^bAll experiments repeated ≥3 times. ^cRCYs determined from [¹⁸F]NFSI and are decay corrected. ^dProduced as an inseparable 1.2:1 mixture of 3-[¹⁸F]FI:4-[¹⁸F]FI. ^eSee SI for effective SA values that take into account residual parent AA.

showed high bone accumulation (Figure 3), which is indicative of in vivo defluorination of the radiotracer and an obvious barrier to its further clinical development.




Figure 3. Biodistribution at 60 min pi of 4- ^{18}F FL (7), 5- ^{18}F FHL (8) and 5- ^{18}F FBAHL (9) in healthy mice.

The in vivo defluorination of 4- ^{18}F FL is consistent with the propensity for this molecule to undergo γ -lactone formation, liberating fluoride.²⁸ As the rate of lactone formation is strongly influenced by ring size,²⁹ we contemplated the radiosynthesis of 5- ^{18}F fluorohomoleucine (5- ^{18}F FHL (8)), 5- ^{18}F fluoro- β -amino-homoleucine (5- ^{18}F FBAHL (9)), 3- ^{18}F fluorovaline (3- ^{18}F FV (10)), and 3- ^{18}F fluoroisoleucine (3- ^{18}F FI (11)).³⁰ It was expected that defluorination of these amino acids via β - or δ -lactone formation would be greatly attenuated. Moreover, in addition to transporting branched aliphatic and aromatic amino acids, a recent report by Kanai³¹ highlighted the efficient transport of homoleucine and β -aminohomoleucine by LAT1 in HeLa S3 cells. As summarized in Table 1, 5- ^{18}F FHL (8) and 5- ^{18}F FBAHL (9) could be readily prepared and purified without modification to the process established for 4- ^{18}F FL.²¹ The radiofluorination of valine and isoleucine afforded 3- ^{18}F FV (10) and mixtures of 3- and 4- ^{18}F FI (e.g., 11) albeit in lower RCY owing to the decreased rate of these reactions, which is consistent with our earlier findings from the fluorination of aliphatic esters.^{15a} The biodistribution of both 8 and 9 was examined in healthy mice (Figure 3), and we were delighted to find that neither of these radiotracers showed any appreciable accumulation of activity in the bone at 60 min postinjection (PI). The uptake of 5- ^{18}F FHL (8) was also examined in a panel of LAT1-expressing cancer cell lines that included LNCaP, PC3, MCF7 and U87 (glioma).²¹ Again, uptake in these cancer cell lines correlated well with their expected mRNA expression levels for LAT1²⁶ and was substantially blocked by addition of the LAT1 inhibitor BCH,²⁷ suggesting that transport of this radiotracer is significantly mediated by LAT1.

The uptake of 5- ^{18}F FHL (8) in several cancer cell lines and its improved biodistribution over 4- ^{18}F FL inspired us to undertake an imaging study using this tracer in mice bearing human glioma (U87) or prostate cancer (PC3) xenografts. Biodistribution studies indicated high tumor accumulation ($5.9 \pm 0.7\% \text{ID/g}$ ($n = 4$) for U87, $5.6 \pm 3.2\% \text{ID/g}$ ($n = 5$) for PC3 at 60 min PI) of 5- ^{18}F FHL was observed with both U87 and PC3 xenografts.²¹ Combined with low background uptake, 5- ^{18}F FHL provided excellent tumor visualization and high tumor contrast ratios as evidenced in Figure 4.²¹ Excretion of 5-




Figure 4. PET imaging of 5- ^{18}F FHL in mice bearing human glioma (U87) xenografts. Maximum intensity projection images overlaid on CT (a) and standalone PET images (b) of the biodistribution of 5- ^{18}F FHL at 60 min show high accumulation of 5- ^{18}F FHL in the tumor (red arrow).

^{18}F FHL occurred predominantly by renal clearance, with accumulation observed in the pancreas, kidneys and bladder. Tissue time activity curves²¹ obtained in selected organs using dynamic images showed rapid accumulation of 5- ^{18}F FHL in the tumors and pancreas, peaking shortly before 10 min, followed by slow efflux. Low uptake was observed in muscles and bone, further evincing the improved in vivo stability of 5- ^{18}F FHL over the L-leucine derivative 4- ^{18}F FL.

In summary, we have developed a mild ^{18}F -labeling strategy that selectively replaces the tertiary C–H bond in branched aliphatic amino acids with a C– ^{18}F bond. Importantly, this process obviates both complicated precursor synthesis and the use of prosthetic groups. The uptake of both 4- ^{18}F FL and 5- ^{18}F FHL in several cancer cell lines was investigated and found to correlate well with LAT1 expression, highlighting their potential as metabolic PET imaging agents. However, the biodistribution of these two radiotracers differed significantly, with 4- ^{18}F FL displaying high bone uptake suggestive of in vivo defluorination. The imaging ability of 5- ^{18}F FHL was examined in mice bearing human glioma and prostate cancer xenografts and high accumulation was found in the tumors, which provided excellent tumor visualization and no significant defluorination was observed. Notably, this convenient radiofluorination should enable rapid proof-of-feasibility studies on a variety of related amino acids and biomolecules and support high throughput production of radiotracers.

■ ASSOCIATED CONTENT

📄 Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.6b11533.

Experimental procedures, characterization, cell uptake, biodistribution and imaging data (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*rbritton@sfu.ca
*pschaffer@triumf.ca
*rainer_e.martin@roche.com
*fbenard@bccrc.ca

ORCID

Rainer E. Martin: 0000-0001-7895-497X

Robert Britton: 0000-0002-9335-0047

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by an NSERC Discovery Grant to R.B., a MSFHR Career Investigator Award to R.B., a Hoffmann-La Roche Fellowship (RPF) for M.B.N. and a CCSRI Innovation Grant to P.S. The authors thank the TRIUMF TR13 cyclotron team, in particular David Prevost, Linda Graham and Samuel Varah. TRIUMF receives federal funding via a contribution agreement with the National Research Council of Canada. The authors also thank Nadine Colpo at BC Cancer Research imaging facility for technical support.

REFERENCES

- (1) (a) Phelps, M. E. *Proc. Natl. Acad. Sci. U. S. A.* **2000**, *97*, 9226. (b) Ametamey, S. M.; Honer, M.; Schubiger, P. A. *Chem. Rev.* **2008**, *108*, 1501.
- (2) Gambhir, S. S. *Nat. Rev. Cancer* **2002**, *2*, 683.
- (3) Sharma, R.; Aboagye, E. *Br. J. Pharmacol.* **2011**, *163*, 1565.
- (4) (a) Zhu, A.; Lee, D.; Shim, H. *Semin. Oncol.* **2011**, *38*, 55. (b) Plathow, C.; Weber, W. A. *J. Nucl. Med.* **2008**, *49*, 43S.
- (5) (a) Som, P.; Atkins, H. L.; Bandyopadhyay, D.; Fowler, J. S.; MacGregor, R. R.; Matsui, K.; Oster, Z. H.; Sacker, D. F.; Shiue, C. Y.; Turner, H.; Wan, C.-N.; Wolf, A. P.; Zabinski, S. V. *J. Nucl. Med.* **1980**, *21*, 670. (b) Kelloff, J.; Hoffman, J. M.; Johnson, B.; Scher, H. L.; Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O'shaughnessy, J.; Guyton, K. Z.; Mankoff, D. A.; Shankar, L.; Larson, S. M.; Sigman, C. C.; Schilsky, R. L.; Sullivan, D. C. *Clin. Cancer Res.* **2005**, *11*, 2785.
- (6) Langen, K.-J.; Hamacher, K.; Weckesser, M.; Floeth, F.; Stoffels, G.; Bauer, D.; Coenen, H. H.; Pauleit, D. *Nucl. Med. Biol.* **2006**, *33*, 287.
- (7) Qu, W.; Zha, Z.; Ploessl, K.; Lieberman, B. P.; Zhu, L.; Wise, D. R.; Thompson, C. B.; Kung, H. F. *J. Am. Chem. Soc.* **2011**, *133*, 1122.
- (8) (a) Huang, C.; McConathy, J. *J. Nucl. Med.* **2013**, *54*, 1007. (b) Jager, P. L.; Vaalburg, W.; Pruim, J.; de Vries, E. G.; Langen, K. J.; Piers, D. A. *J. Nucl. Med.* **2001**, *42*, 432. (c) Laverman, P.; Boerman, O. C.; Corstens, F. H.; Oyen, W. J. *Eur. J. Nucl. Med. Mol. Imaging* **2002**, *29*, 681. (d) McConathy, J.; Goodman, M. M. *Cancer Metastasis Rev.* **2008**, *27*, 555.
- (9) (a) Wang, Q.; Holst, J. *Am. J. Cancer Res.* **2015**, *5*, 1281. (b) Fuchs, B. C.; Bode, B. P. *Semin. Cancer Biol.* **2005**, *15*, 254. (c) Uchino, H.; Kanai, Y.; Kim, D. K.; Wempe, M. F.; Chairoungdua, A.; Morimoto, E.; Anders, M. W.; Endou, H. *Mol. Pharmacol.* **2002**, *61*, 729.
- (10) Saxton, R. A.; Knockenhauer, K. E.; Wolfson, R. L.; Chantranupong, L.; Pacold, M. E.; Wang, T.; Schwartz, T. U.; Sabatini, D. M. *Science* **2016**, *351*, 53.
- (11) (a) Mu, F.; Mangner, T. J.; Chugani, H. T. *J. Labelled Compd. Radiopharm.* **2005**, *48*, S189. (b) Alkonyi, B.; Chugani, H. T.; Muzik, O.; Chugani, D. C.; Sundaram, S. K.; Kupsky, W. J.; Batista, C. E.; Juhász, C. *J. Neuroimaging* **2012**, *22*, 177.
- (12) (a) Schuster, D. M.; Nanni, C.; Fanti, S.; Oka, S.; Okudaira, H.; Inoue, Y.; Sørensen, J.; Owenius, R.; Choyke, P.; Turkbey, B.; Bogsrud, T. V.; Bach-Gansmo, T.; Halkar, R. K.; Nye, J. A.; Odewole, O. A.; Savir-Baruch, B.; Goodman, M. M. *J. Nucl. Med.* **2014**, *55*, 1986. (b) McConathy, J.; Voll, R. J.; Yu, W.; Crowe, R. J.; Goodman, M. M. *Appl. Radiat. Isot.* **2003**, *58*, 657.
- (13) Liu, Z.; Chen, H.; Chen, K.; Shao, Y.; Kiesewetter, D. O.; Niu, G.; Chen, X. *Sci. Adv.* **2015**, *1*, e1500694.
- (14) (a) For late-stage C-H ^{18}F -fluorination with ^{18}F F_2 , see: Firnau, G.; Chirakal, R.; Garnett, E. S. *J. Nucl. Med.* **1984**, *25*, 1228. (b) with ^{18}F $\text{CH}_3\text{CO}_2\text{F}$, see: Chirakal, R.; Firnau, G.; Couse, J.; Garnett, E. S. *Int. J. Appl. Radiat. Isot.* **1984**, *35*, 651. (c) For benzylic C-H ^{18}F -fluorination, see: Huang, X.; Liu, W.; Ren, H.; Neelamegam, R.; Hooker, J. M.; Groves, J. T. *J. Am. Chem. Soc.* **2014**, *136*, 6842.
- (15) (a) Halperin, S. D.; Fan, H.; Chang, S.; Martin, R. E.; Britton, R. *Angew. Chem., Int. Ed.* **2014**, *53*, 4690. (b) Halperin, S. D.; Kwon, D.; Holmes, M.; Regalado, E. L.; Campeau, L.-C.; DiRocco, D. A.; Britton, R. *Org. Lett.* **2015**, *17*, S200. (c) Nodwell, M. B.; Bagai, A.; Halperin, S. D.; Martin, R. E.; Knust, H.; Britton, R. *Chem. Commun.* **2015**, *51*, 11783.
- (16) Renneke, R. F.; Pasquali, M.; Hill, C. L. *J. Am. Chem. Soc.* **1990**, *112*, 6585.
- (17) Rueda-Becerril, M.; Sazepin, C. C.; Leung, J. C. T.; Okbinoglu, T.; Kennepohl, P.; Paquin, J.-F.; Sammis, G. M. *J. Am. Chem. Soc.* **2012**, *134*, 4026.
- (18) Teare, H.; Robins, E. G.; Årstad, E.; Luthra, S. K.; Gouverneur, V. *Chem. Commun.* **2007**, 2330.
- (19) (a) Buckingham, F.; Kirjavainen, A. K.; Forsback, S.; Krzyczmonik, A.; Keller, T.; Newington, I. M.; Glaser, M.; Luthra, S. K.; Solin, O.; Gouverneur, V. *Angew. Chem., Int. Ed.* **2015**, *54*, 13366. (b) Buckingham, F.; Gouverneur, V. *Chem. Sci.* **2016**, *7*, 1645. (c) Teare, H.; Robins, E. G.; Kirjavainen, A.; Forsback, S.; Sandford, G.; Solin, O.; Luthra, S. K.; Gouverneur, V. *Angew. Chem., Int. Ed.* **2010**, *49*, 6821.
- (20) For the synthesis of 4- ^{18}F FL, see: (a) Padmakshan, D.; Bennett, S. A.; Otting, G.; Easton, C. J. *Synlett* **2007**, 1083. (b) Truong, V. L.; Gauthier, J. Y.; Boyd, M.; Roy, B.; Scheiget, J. *Synlett* **2005**, 1279.
- (21) See [Supporting Information](#) for experimental details, description of apparatuses, cell uptake, biodistribution and imaging data.
- (22) Demling, J.; Langer, K.; Wörthmüller, M.; Yusufu, V. *Amino Acids* **1993**, *5*, 253.
- (23) The SA of ^{18}F NFSI, and consequently 7–10, can be increased by lengthening the irradiation time of ^{18}O O_2 ; a 5–10 min irradiation was chosen to limit radioactive exposure. Additionally, high SA ^{18}F F_2 (up to 55 GBq μmol^{-1}) can be prepared using a process described in: Bergman, J.; Solin, O. *Nucl. Med. Biol.* **1997**, *24*, 677.
- (24) Bishop, A.; Satyamurthy, N.; Bida, G.; Phelps, M.; Barrio, J. R. *Nucl. Med. Biol.* **1996**, *23*, 385.
- (25) The SA of clinical doses of L-6- ^{18}F fluoro-DOPA (FDOPA) are typically 4–8 MBq μmol^{-1} . See: Turjanski, N.; Sawle, G. V.; Playford, E. D.; Weeks, R.; Lammerstma, A. A.; Lees, A. J.; Brooks, D. J. *J. Neurol., Neurosurg. Psychiatry* **1994**, *57*, 688.
- (26) Barretina, J.; et al. *Nature* **2012**, *483*, 603.
- (27) Kim, C. S.; Cho, S. H.; Chun, H. S.; Lee, S. Y.; Endou, H.; Kanai, Y.; Kim, D. K. *Biol. Pharm. Bull.* **2008**, *31*, 1096.
- (28) Limanto, J.; Shafiee, A.; Devine, P. N.; Upadhyay, V.; Desmond, R. A.; Foster, B. R.; Gauthier, D. R.; Reamer, R. A.; Volante, R. P. *J. Org. Chem.* **2005**, *70*, 2372.
- (29) Galli, C.; Illuminati, G.; Mandolini, L.; Tamborra, P. *J. Am. Chem. Soc.* **1977**, *99*, 2591.
- (30) The fluorination of 1-aminocyclobutane carboxylic acid (a potential precursor to FACBC), phenylalanine, tyrosine, histidine, tryptophan and two Leu-containing dipeptides was also explored. While the amino acids failed to fluorinate to any appreciable degree (<5%), the dipeptides Phe-Leu (48%, 6 h) and Tyr-Leu (24%, 6 h) fluorinated cleanly on the Leu residue, though the reaction time may be impractical for radiotracer synthesis (see [Supporting Information](#) for full details).
- (31) Nagamori, S.; Wiryasermkul, P.; Okuda, S.; Kojima, N.; Hari, Y.; Kiyonaka, S.; Mori, Y.; Tominaga, H.; Ohgaki, R.; Kanai, Y. *Amino Acids* **2016**, *48*, 1045.